A male patient in first remission of acute myeloid leukemia was offered a hemopoietic cell transplant from an unrelated female donor. He received reduced-intensity conditioning (RIC) with Fludarabine 30 mg/m2 iv × 5 day, Busulphan 3.2 mg/kg iv × 2 days, and Alemtuzumab 20 mg/day iv × 5 days, followed by donor blood stem cell infusion. The cell dose was 3.7 × 106 CD34+ cells per kilogram recipient weight. Cyclosporine A was administered from day +1.
Leukemia Anemia Bilirubin Cyclosporine Vancomycin
This is a preview of subscription content, log in to check access
Bolan CD, Leitman SF, Griffith LM, et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood. 2001;98:1687–94.PubMedCrossRefGoogle Scholar
Mijovic A, Abdallah A, Pearce L, et al. Effects on erythropoiesis of alemtuzumab-containing reduced intensity and standard conditioning regimes. Br J Haematol. 2008;142:444–52.PubMedCrossRefGoogle Scholar